Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05800015 · ClinicalTrials.gov registry record · Phase 2
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Regeneron Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 950
- Enrollment target
- 20
- Study locations
NCT05800015 is a Phase 2 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Regeneron Pharmaceuticals. The registered enrollment target is 950 participants, above the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (45% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT05800015, a Phase 2 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Regeneron Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 950 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is researching an investigational drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and chemotherapy, individually called a "study drug" or collectively called "study drugs". 'Investigational' means that the study drug is not approved for use outside of this study by any Health Authority. Examples of chemotherapy drugs include the following: Paclitaxel plus carboplatin, and Pemetrexed plus cisplatin. The study is being conducted in patients who have advanced non-small cell lung cancer (NSCLC). The aim of the study is to see how effective the combination of fianlimab, cemiplimab, and chemotherapy is for treating advanced NSCLC, in comparison with cemiplimab and chemotherapy. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much of each study drug is in your blood at different times * Whether the body makes antibodies against the study drugs (which could make the drug less effective or could lead to side effects) * How administering the study drugs might improve your quality of life
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Pemetrexed
- DRUG Paclitaxel
- DRUG fianlimab
- DRUG cemiplimab
Study Locations (20)
California
- The Oncology Institute of Hope & Innovation - Cerritos
- Crosson Cancer Institute - Fullerton
- St. Joseph Hospital Orange - Orange
- Desert Hematology Oncology Medical Group Incorporated - Rancho Mirage
- Emad Ibrahim, MD, Inc. - Redlands
- PIH Health Hospital - Whittier
Florida
- Clermont Oncology Center - Clermont
- Miami Veterans Administration HealthCare System - Miami
- Mid Florida Hematology and Oncology Center - Orange City
- Tallahassee Memorial Healthcare - Tallahassee
Arizona
- Arizona Clinical Research Center - Tucson
- Yuma Regional Medical Center - Yuma
Illinois
- University of Illinois - Chicago
- Northwest Oncology and Hematology - Rolling Meadows
Colorado
- Rocky Mountain Regional VA Medical Center - Aurora
Connecticut
- Yale Cancer Center - New Haven
Louisiana
- Mary Bird Perkins Cancer Center - Baton Rouge
Mississippi
- Hattiesburg Clinic - Hattiesburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 950 participants |
| Start Date | 2023-08-08 |
| Est. Completion | 2031-12-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05800015
The ClinicalTrials.gov registry entry for NCT05800015 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 950 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (45% higher). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT05800015 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT05800015 about?
NCT05800015 is a clinical study titled "A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer". This study is researching an investigational drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and chemotherapy, individually called a "study drug" or collectively called "study drugs". 'Investigational' means that the study drug is not approved for use outsid...
What is the current status of trial NCT05800015?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 950 participants. The study started on 2023-08-08. Estimated completion is 2031-12-23.
What conditions does trial NCT05800015 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT05800015?
The interventions under investigation include: Carboplatin (DRUG), Pemetrexed (DRUG), Paclitaxel (DRUG), fianlimab (DRUG), cemiplimab (DRUG).
Who is sponsoring clinical trial NCT05800015?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05800015 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.